Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Promising 3-Drug Regimen for Advanced Gastric Cancer, Regardless of PD-L1 Expression

TON - April 2020, Vol 13, No 2 - Gastrointestinal Cancers
Wayne Kuznar

San Francisco, CA—Second-line treatment with a 3-drug regimen that included the PD-1 inhibitor nivolumab (Opdivo), the VEGF receptor antagonist ramucirumab (Cyramza), and chemotherapy with the taxane paclitaxel, showed durable and impressive response rates, regardless of PD-L1 expression, in patients with advanced gastric cancers. Shuichi Hironaka, MD, PhD, Chiba Cancer Center, Japan, reported the study results at the 2020 Gastrointestinal Cancers Symposium.

In this single-arm phase 1/2 clinical trial, the overall response rate (ORR) with the triplet regimen was 37.2%, and all responses were partial. The median progression-free survival (PFS) was 5.1 months; the PFS was not influenced by the patient’s Combined Positive Score (CPS), which assesses PD-L1 expression in solid tumors. The median overall survival (OS) was 13.1 months, which was not different between the 2 cohorts of patients with low and high CPS, representing the level of PD-L1 expression.

“The impact of PD-L1 expression on the clinical outcome for this combination is not clear,” said Dr Hironaka. “Long-term overall survival was promising for further investigation of this combination.”

Promising Regimen for Advanced Gastric Cancer

This 3-drug combination of nivolumab, paclitaxel, and ramucirumab was investigated in patients with advanced gastric cancer whose disease was refractory to or who were intolerant of first-line combination chemotherapy with platinum and fluoropyrimidine.

“Synergistic antitumor activity had previously been reported with simultaneous blockade of PD-1 and taxanes, as well as PD-1 and vascular endothelial growth factor receptor,” said Dr Hiro­naka, explaining the rationale for this 3-drug combination.

At baseline, 74.4% of the patients had stage IV gastric cancer, and 25.6% had recurrent disease. Approximately half (51.2%) had 2 metastatic sites, and 27.9% had ≥3 metastatic sites. Mismatch repair deficiency status was proficient in 88.4% and was unknown in the remaining 11.6% of patients.

At level 0 in phase 1 of the study, patients received nivolumab (1 mg/kg on days 1 and 15) combined with paclitaxel (80 mg/m2 on days 1, 8, and 15) and ramucirumab (8 mg/kg on days 1 and 15) every 4 weeks. At dose level 1, nivolumab was dosed at 3 mg/kg on days 1 and 15 and the other drugs were dosed as per level 0. After feasibility was established in the phase 1 portion of 6 patients, an additional 37 patients were enrolled in the phase 2 portion, with 6-month PFS rate as the primary end point.

With a median follow-up of 23.2 months, the 6-month PFS rate was 46.4%. When 20 patients who achieved stable disease were considered, the disease control rate was 83.7%.

The results were stratified according to the patients’ CPS. A total of 32 (60.5%) patients had a score ≥1, and 13 (39.5%) had a score <1. In patients with a score of <1, the ORR was 30.8% (4 partial responses) compared with 46.2% (12 partial responses) in patients with a score ≥1. When the score of ≥10 was used as the cut point, the ORR was 37.5% in those with a CPS <10 versus 57.1% in patients with a score of ≥10.

The 6-month PFS was not significantly different based on the CPS cutoffs.

The median OS was 13.1 months. The 12- and 18-month OS rates were 55.8% and 32.1%, respectively. As with the PFS, the OS was not significantly different between patients with low versus high PD-L1 expression, as determined by the CPS. Further biomarker analyses are ongoing.

Safety Profile

The tolerability of the 3-drug regimen was good, according to Dr Hironaka. The most common grade 3 or 4 adverse event was a decrease in the neutrophil count, experienced by 33 (76.7%) patients. A total of 20 (46.5%) patients had a decrease in white blood cell count. Dose-limiting toxicities were reported in 2 patients at dose level 1 (1 patient had febrile neutropenia and the other patient had neutropenia for 8 days).

Related Items
Two Ways to Target Tumors with KRAS Mutations
Wayne Kuznar
Web Exclusives published on August 17, 2020 in AACR Highlights
A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
Wayne Kuznar
TON - April 2020, Vol 13, No 2 published on April 16, 2020 in ASCO
Cabozantinib-Atezolizumab Combination Shows Activity in Difficult-to-Treat Prostate Cancer
Wayne Kuznar
TON - April 2020, Vol 13, No 2 published on April 16, 2020 in Immunotherapy
Pemigatinib Effective in Patients with Cholangiocarcinoma and FGFR2 Fusion or Rearrangement
Wayne Kuznar
TON - February 2020, Vol 13, No 1 published on February 5, 2020 in Cholangiocarcinoma
Practice-Changing Results: Ivosidenib First Targeted Therapy to Show Benefits in Patients with Cholangiocarcinoma and IDH1 Mutation
Wayne Kuznar
TON - February 2020, Vol 13, No 1 published on February 5, 2020 in Cholangiocarcinoma
FDA Grants Approval to Avapritinib for Patients with GIST
Web Exclusives published on January 13, 2020 in FDA Updates, Gastrointestinal Cancers, In the News, Rare Cancers
Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management
Wayne Kuznar
TON - December 2019, Vol 12, No 6 published on December 5, 2019 in Cholangiocarcinoma
Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management
Wayne Kuznar
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Pain Management, NCCN
First Positive Showing for Mesothelin-Directed CAR T-Cell Therapy in Solid Tumors
Wayne Kuznar
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Immunotherapy
Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Drug Updates, FDA Updates, Gastrointestinal Cancers
Last modified: July 30, 2020